In conclusion, we developed a noninvasive radiomic strategy nominated as RIS model which has been approved with higher accuracy to monitor TIME status, predict clinical outcome, and evaluate anti-PD-1 immunotherapy responsiveness for HCC patients. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.